Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Yulong Gao(The University of Queensland), Mark J. Smyth(Peter MacCallum Cancer Centre), Michele W.L. Teng(The University of Queensland), Michael Hölzel(University of Bonn), Christian Engwerda(QIMR Berghofer Medical Research Institute), Stephen J. Blake(QIMR Berghofer Medical Research Institute), Éric Vivier(Innate Pharma (France)), Jai Rautela(Norwood Hospital), Tobias Bald(QIMR Berghofer Medical Research Institute), Fernando Souza-Fonseca-Guimarães(The University of Queensland), Jason S. Lee(The University of Queensland), Arabella Young(The University of Queensland), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Shin Foong Ngiow(Parker Institute for Cancer Immunotherapy), Kyohei Nakamura(QIMR Berghofer Medical Research Institute), Gabrielle T. Belz(The University of Queensland), Susanna S. Ng(University Hospital Bonn), Kazuyoshi Takeda(National Center of Neurology and Psychiatry), Laurence Zitvogel(Institut Gustave Roussy), Laurent Bartholin(Université Claude Bernard Lyon 1), Nicholas D. Huntington(The University of Melbourne), Jasmin Straube(QIMR Berghofer Medical Research Institute), Juming Yan(Xuzhou Medical College), Nicola Waddell(QIMR Berghofer Medical Research Institute)
Cited by 639
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Functions of natural killer cells
|Nature Immunology|2008|3.8k
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
TLR3 Deficiency in Patients with Herpes Simplex Encephalitis
|Science|2007|1.1k